SNP:BVBOMV Petrom SA Analysis
Data as of 2026-05-30 - not real-time
$475.62
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Synopsys is trading at $475.62, well below its DCF‑derived fair value of $626, implying roughly a 17% upside potential. Trailing PE of 108 is far above the industry average of 42, but the forward PE of 27.6 reflects a sharp earnings acceleration forecast (forward EPS $17.21 vs trailing $4.38). Revenue is expanding at a robust 42% year‑over‑year with an 82.6% gross margin, underscoring strong growth fundamentals.
Technically, the stock sits beneath the 20‑day SMA ($505) but above the 50‑day SMA ($461), while the MACD is bearish and the RSI sits at 43, suggesting limited short‑term momentum. Volatility is elevated at 46% over the past 30 days and beta is high (≈1.76), indicating the share price is more sensitive than the market.
Given the valuation gap, solid growth trajectory, and strategic AI‑driven EDA initiatives—including a partnership with Arm—our view is bullish for the medium to long term, while short‑term positioning should be cautious pending a clearer technical breakout.
Technically, the stock sits beneath the 20‑day SMA ($505) but above the 50‑day SMA ($461), while the MACD is bearish and the RSI sits at 43, suggesting limited short‑term momentum. Volatility is elevated at 46% over the past 30 days and beta is high (≈1.76), indicating the share price is more sensitive than the market.
Given the valuation gap, solid growth trajectory, and strategic AI‑driven EDA initiatives—including a partnership with Arm—our view is bullish for the medium to long term, while short‑term positioning should be cautious pending a clearer technical breakout.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price below 20‑day SMA
- bearish MACD histogram
- elevated volatility and beta
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- undervalued versus DCF fair value
- strong 42% revenue growth
- forward PE compression to 27.6
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- AI‑driven EDA market tailwinds
- high gross margin (~83%)
- strategic collaboration with Arm
Key Metrics & Analysis
Financial Health
Revenue Growth41.90%
Profit Margin8.91%
P/E Ratio108.6
ROE3.82%
ROA1.49%
Debt/Equity35.57
P/B Ratio3.0
Op. Cash Flow$2.8B
Free Cash Flow$3.5B
Industry P/E41.9
Technical Analysis
TrendNeutral
RSI43.7
Support$469.37
Resistance$539.48
MA 20$505.15
MA 50$460.84
MA 200$469.03
MACDBearish
VolumeIncreasing
Fear & Greed Index94.07
Valuation
Fair Value$626.07
Target Price$558.46
Upside/Downside17.42%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.76
Volatility46.54%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.